An open-label study of quetiapine in the treatment of fibromyalgia.

摘要: The aim of this exploratory study was to systematically assess the potential effectiveness and tolerability quetiapine, an atypical antipsychotic, for treatment patients with fibromyalgia. This a unicentre, open-label conducted in thirty-five outpatients, 18 years or older, who met ACR criteria fibromyalgia had not satisfactorily responded their previous treatment. Quetiapine, flexibly dosed (25-100 mg/day), added original regimen 12 weeks. primary outcome measure mean change from baseline endpoint Fibromyalgia Impact Questionnaire (FIQ) total score. Secondary efficacy measures included changes scores Clinical Global Impression (CGI) Severity scale, Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), State-Trait Anxiety (STAI), 12-Item Short Form Health Survey (SF-12), individual items FIQ. Thirty (85.7%) (mean age 47+/-7.9, 93.3% females) postbaseline evaluation constituted intent-to-treat sample. Mean FIQ score decreased significantly by 10.2 points 63.2 53.0 at (p =0.50) were encountered fatigue, stiffness SF-12 mental component summary. Quetiapine safely administered well tolerated. Despite lack effect on pain, significant relevant improvement overall quality life suggests that quetiapine may be valuable drug should further tested double-blind, placebo-controlled trials.